FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

May 1, 2025 - 22:00
 0  1
FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
DURHAM, N.C., April 30, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0